Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?

Porphyria cutanea tarda (PCT) is the most common porphyria and has a strong association with hepatitis C virus (HCV) infection and iron overload. Previous HCV treatment regimens, including interferon with or without ribavirin, may precipitate PCT relapse. Few case reports have shown that newer oral...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Jason J., Sterling, Richard K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126551/
https://www.ncbi.nlm.nih.gov/pubmed/34007857
http://dx.doi.org/10.14309/crj.0000000000000581
_version_ 1783693784482054144
author John, Jason J.
Sterling, Richard K.
author_facet John, Jason J.
Sterling, Richard K.
author_sort John, Jason J.
collection PubMed
description Porphyria cutanea tarda (PCT) is the most common porphyria and has a strong association with hepatitis C virus (HCV) infection and iron overload. Previous HCV treatment regimens, including interferon with or without ribavirin, may precipitate PCT relapse. Few case reports have shown that newer oral therapies, such as direct-acting antiviral agents, can successfully treat PCT parallel with HCV treatment. We present a case of a patient with non–iron-associated mixed porphyria that dramatically improved with direct-acting antiviral agent therapy for his HCV supporting the association of porphyria with chronic HCV.
format Online
Article
Text
id pubmed-8126551
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-81265512021-05-17 Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future? John, Jason J. Sterling, Richard K. ACG Case Rep J Case Report Porphyria cutanea tarda (PCT) is the most common porphyria and has a strong association with hepatitis C virus (HCV) infection and iron overload. Previous HCV treatment regimens, including interferon with or without ribavirin, may precipitate PCT relapse. Few case reports have shown that newer oral therapies, such as direct-acting antiviral agents, can successfully treat PCT parallel with HCV treatment. We present a case of a patient with non–iron-associated mixed porphyria that dramatically improved with direct-acting antiviral agent therapy for his HCV supporting the association of porphyria with chronic HCV. Wolters Kluwer 2021-05-14 /pmc/articles/PMC8126551/ /pubmed/34007857 http://dx.doi.org/10.14309/crj.0000000000000581 Text en © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
John, Jason J.
Sterling, Richard K.
Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
title Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
title_full Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
title_fullStr Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
title_full_unstemmed Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
title_short Hepatitis-Induced Porphyria: Are Direct-Acting Antiviral Agents the Way of the Future?
title_sort hepatitis-induced porphyria: are direct-acting antiviral agents the way of the future?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126551/
https://www.ncbi.nlm.nih.gov/pubmed/34007857
http://dx.doi.org/10.14309/crj.0000000000000581
work_keys_str_mv AT johnjasonj hepatitisinducedporphyriaaredirectactingantiviralagentsthewayofthefuture
AT sterlingrichardk hepatitisinducedporphyriaaredirectactingantiviralagentsthewayofthefuture

Ejemplares similares